BRBS Blue Ridge Bancshares Inc

Filed Pursuant to Rule 424(b)(3)
Registration Statement No. 333-280939

Prospectus

96,809,999 Shares of Common Stock

This prospectus relates to the offer and sale of up to 96,809,999 shares of our common stock, no par value per share (the “Securities”), including 26,195,999 shares of our common stock issuable upon the exercise of warrants to purchase our common stock outstanding as of the date hereof and 16,692,000 shares of our common stock issuable upon the conversion or exchange of our Mandatorily Convertible Cumulative Perpetual Preferred Stock, Series C, par value $50.00 per share (the “Series C Preferred Stock”) and the exercise of warrants to purchase our Series C Preferred Stock following such conversion or exchange, by certain selling shareholders identified herein (the “Selling Shareholders”).

The Securities were issued by us to the Selling Shareholders as part of the private placements of our securities that closed in the second quarter of 2024, as described further in this prospectus. We are registering the resale of the Securities pursuant to registration rights agreements entered into with the Selling Shareholders in connection with such private placements.

The Selling Shareholders may sell all or a portion of the Securities from time to time, in amounts, at prices and on terms as they may determine. The Securities may be sold by any means described in the section of this prospectus entitled “Plan of Distribution” beginning on page 24.

We will not receive any proceeds from the sale of the Securities by the Selling Shareholders. We will, however, receive cash proceeds equal to the total exercise price of any warrants issued in the private placements referred to above and described further in this prospectus that are exercised for cash. We will receive no cash if and to the extent that such warrants are exercised pursuant to the net, or “cashless,” exercise feature of the warrants.

Our common stock is listed on the NYSE American market under the symbol “BRBS.” On July 29, 2024, the closing price of our common stock on the NYSE American market was $2.79 per share.

Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described under the heading “Risk Factors” beginning on page 6 of this prospectus, as well as the risks and uncertainties described in the other documents that are incorporated or deemed to be incorporated by reference into this prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the Securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The Securities are and will not be savings accounts, deposits or other obligations of any bank and are not insured or guaranteed by the Federal Deposit Insurance Corporation, the Deposit Insurance Fund or any other governmental agency or instrumentality.

The date of this prospectus is July 29, 2024.

TABLE OF CONTENTS

i

ABOUT THIS PROSPECTUS

This document is called a prospectus and is part of a registration statement that we have filed with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration process. Under this shelf registration process, the Selling Shareholders may, from time to time, sell the Securities described in this prospectus in one or more offerings or resales.

The registration statement containing this prospectus, including exhibits to the registration statement, provides additional information about us and the Securities offered under this prospectus and any prospectus supplement. We have filed and plan to continue to file other documents with the SEC that contain information about us and our business. The registration statement and other reports can be found on the SEC Internet website mentioned under the heading “Where You Can Find More Information.”

You should rely only on the information contained in or incorporated by reference into this prospectus. We have not, and the Selling Shareholders have not, authorized anyone to provide you with information different from that contained in this prospectus or the documents incorporated by reference herein. You should not assume that information contained in this prospectus or in any applicable prospectus supplement is accurate as of any date other than their respective dates, regardless of the time of delivery of this prospectus or any supplement to this prospectus or of any sale of the Securities. In the case of information contained in documents we file with the SEC and incorporate by reference into this prospectus, you should assume that such information is accurate only as of the respective dates of those documents.

Unless the context requires otherwise, in this prospectus we use the terms “we,” “us,” “our,” “Blue Ridge” and the “Company” to refer to Blue Ridge Bankshares, Inc. and its subsidiaries on a consolidated basis. The term “Blue Ridge Bank” refers to Blue Ridge Bank, National Association, our bank subsidiary.

WHERE YOU CAN FIND MORE INFORMATION

This prospectus is a part of a registration statement on Form S-3 that we have filed with the SEC under the Securities Act of 1933, as amended (the “Securities Act”). This prospectus does not contain all the information set forth in the registration statement. For further information with respect to us and the Securities offered by this prospectus, reference is made to the registration statement, including the exhibits to the registration statement and the documents incorporated by reference.

We file annual, quarterly and current reports, proxy statements and other information with the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our SEC filings, including the registration statement, are available to the public on the SEC’s Internet website at www.sec.gov. Our SEC filings are also available at no cost on our website at www.mybrb.com, as soon as reasonably practicable after we file such documents with the SEC. We are not incorporating the information on our website into this prospectus, and the information on the website is not included in, nor is it a part of, this prospectus or any prospectus supplement. Our SEC file number is 001-39165.

1

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

The SEC allows us to “incorporate by reference” into this prospectus the information we file with the SEC, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. Information incorporated by reference is considered to be part of this prospectus, except for any information that is superseded by information included directly in this prospectus or in later filed documents incorporated by reference into this prospectus.

We incorporate by reference into this prospectus the documents listed below and any future filings we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the initial filing of the registration statement of which this prospectus is a part and prior to the effectiveness of such registration statement and (ii) after the date of this prospectus but before the termination of the offering of the securities covered by this prospectus, except to the extent that any information contained in such filings is deemed “furnished” in accordance with SEC rules (unless otherwise indicated therein):

Information filed with the SEC after the date of this prospectus will automatically update and supersede information contained in or previously incorporated by reference into this prospectus.

We will provide, without charge, to each person (including any beneficial owner) who receives a copy of this prospectus, upon the written or oral request of any such person, a copy of any or all of these filings (other than exhibits to such documents, unless that exhibit is specifically incorporated by reference into that filing). Requests should be directed to: Blue Ridge Bankshares, Inc., 1801 Bayberry Court, Suite 101, Richmond, Virginia 23226, Attention: Investor Relations (telephone: (540) 743-6521). These documents are also available on our website at www.mybrb.com. You may also inspect these documents and other information without charge on the SEC’s website at www.sec.gov. Except for incorporated documents, information contained on our website or the SEC’s website is not a prospectus and does not constitute part of this prospectus.

2

3

4

5

RISK FACTORS

An investment in the Securities involves a high degree of risk. Before making an investment decision, you should carefully read and consider the risk factors set forth below and in our most recent Annual Report on Form 10-K under the heading “Risk Factors,” as well as any updated or additional disclosure about risk factors included in any of our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K or other filings that we have made or may make with the SEC since the date of the latest Annual Report on Form 10-K that are incorporated by reference into this prospectus. If any of the risks occur, our business, financial condition and operating results may be materially adversely affected. In that event, the trading price of the Securities could decline, and you could lose all or part of your investment. For more information, see “Where You Can Find More Information” and “Incorporation of Certain Information by Reference.”

The price of our common stock may fluctuate significantly, which may make it difficult for you to resell shares of common stock owned by you at prices you find attractive.

Our common stock price may fluctuate significantly as a result of a variety of factors, many of which are beyond our control. These factors include, in addition to those described in the section entitled “Forward-Looking and Cautionary Statements”:

In addition, volatility in the stock market has had a significant effect on the market price of securities issued by many companies, including for reasons unrelated to their operating performance. These broad market fluctuations may adversely affect our stock price, notwithstanding our operating results. We expect that the market price of our common stock will continue to fluctuate and there can be no assurances about the levels of the market prices for our common stock.

Sales of large amounts of our common stock, or the perception that sales could occur, may depress our stock price.

The market price of our common stock could drop if our existing shareholders decide to sell their shares, especially certain of the Selling Shareholders. As of July 19, 2024, Kenneth L. Lehman owned 19,998,257 common shares, or about 27.2% of the outstanding shares of our common stock, and Castle Creek Capital Partners VIII, LP (“Castle Creek”) owned 593,078 common shares and owned all 2,732 outstanding shares of our Series C Preferred Stock, which are convertible or exchangeable into

6

approximately 10,928,000 shares of our common stock in certain circumstances, which, taken together, would constitute about 13.6% of the outstanding shares of our common stock (taking into account such additional shares of our common stock upon conversion or exchange). All of the other Selling Shareholders also hold shares of our common stock. The market price could drop significantly if one or more of such Selling Shareholders sold substantial amounts of our common stock or other investors perceive sales to be imminent. We cannot foresee the impact of such potential sales on the market, but it is possible that if a significant percentage of shares were attempted to be sold within a short period of time, the market for our shares would be adversely affected. Even if a substantial number of sales do not occur within a short period of time, the mere existence of this “market overhang” could have a negative impact on the market for our common stock.

In addition, as of July 19, 2024, Mr. Lehman holds a warrant to purchase 10,000,000 shares of our common stock at an exercise price of $2.50 per share, subject to certain adjustments, and Castle Creek holds a warrant to purchase 1,441 shares of our Series C Preferred Stock at an exercise price of $10,000 per share, which are convertible or exchangeable upon exercise into 5,764,000 shares of our common stock in certain circumstances and subject to certain adjustments. Certain of the other Selling Shareholders also hold warrants to purchase, in the aggregate, 16,195,999 shares of our common stock. The exercise of such warrants and the sale of the underlying shares of common stock also could adversely affect the market price of our common stock.

Kenneth L. Lehman and Castle Creek are substantial holders of our securities.

Following the conversion or exchange of the Series C Preferred Stock, we expect that Mr. Lehman will own approximately 19,998,257 common shares, or about 23.7% of the outstanding shares of our common stock, and Castle Creek will own approximately 11,521,078 common shares, or about 13.6% of the outstanding shares of our common stock (in each case, taking into account such additional shares of our common stock upon conversion or exchange). Pursuant to the terms of the Securities Purchase Agreement, Mr. Lehman has the right to appoint one representative on our Board of Directors, and Castle Creek has the right to appoint two representatives on our Board of Directors. Mr. Lehman and/or Castle Creek may have individual economic interests that are different from the other’s interests and different from the interests of our other shareholders.

Certain provisions under our articles of incorporation and applicable law may make it difficult for others to obtain control of our corporation even if such a change in control may be favored by some shareholders.

Certain provisions in our articles of incorporation and applicable Virginia corporate and banking law may have the effect of discouraging a change in control of the Company even if such a transaction is favored by some of our shareholders and might result in shareholders receiving a substantial premium over the current market price of our common shares. The primary purpose of these provisions is to encourage negotiations with our management by persons interested in acquiring control of the Company. These provisions may also tend to perpetuate present management and make it difficult for shareholders owning less than a majority of the shares to be able to elect even a single director. See “Description of Capital Stock — Anti-takeover Provisions of our Articles of Incorporation, Bylaws and Virginia Law.”

7

FORWARD-LOOKING AND CAUTIONARY STATEMENTS

Certain information contained in this prospectus and the documents incorporated by reference in this prospectus may include “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. You can identify these statements from our use of the words “may,” “will,” “should,” “could,” “would,” “plan,” “potential,” “estimate,” “project,” “believe,” “intend,” “anticipate,” “expect,” “target” and similar expressions. Examples of forward-looking statements include, but are not limited to, estimates with respect to our financial condition, expected or anticipated revenue, results of operations and business that are subject to various factors which could cause actual results to differ materially from these estimates. These factors include, but are not limited to, the following:

8

The foregoing factors should not be considered exhaustive and should be read together with other cautionary statements that are included in the filings we make from time to time with the SEC. Any one of these risks or factors could have a material adverse impact on our results of operations or financial condition, or cause our actual results, performance or achievements to differ materially from those expressed in, or implied by, forward-looking information and statements contained in or incorporated by reference into this prospectus. Moreover, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on our forward-looking statements. Therefore, we caution you not to place undue reliance on our forward-looking information and statements, which speak only as of the date of this prospectus. We do not undertake to, and will not, update or revise these forward-looking statements after the date hereof, whether as a result of new information, future events, or otherwise.

You should also consider carefully the statements under “Risk Factors” and other sections of this prospectus or any applicable prospectus supplement and the documents we incorporate by reference, which address additional facts that could cause our actual results to differ from those set forth in the forward-looking statements.

9

USE OF PROCEEDS

We will receive no proceeds from the sale of the Securities by the Selling Shareholders.

A portion of the shares of our common stock covered by this prospectus are issuable upon exercise of warrants issued to certain of the Selling Shareholders in the Private Placement and the Spurzem Placement. The exercise price of the outstanding warrants is $2.50 per share, other than with respect to (i) Mr. Spurzem, who holds a warrant to purchase common stock with an exercise price of $2.39 per share and (ii) Castle Creek, which holds a warrant to purchase Series C Preferred Stock with an exercise price of $10,000 per share. We will not receive any cash payment from the Selling Shareholders upon any net, or “cashless,” exercise of the warrants. However, holders of the warrants may also exercise the warrants and pay us the exercise price in cash. To the extent we receive proceeds from the cash exercise of the warrants, we may use such proceeds for general corporate purposes and to reposition business lines, support organic growth and enhance capital levels of Blue Ridge Bank.

10

DESCRIPTION OF CAPITAL STOCK

General

The following description is a summary of the material terms of our capital stock. The summary does not purport to be complete and is subject to, and qualified in its entirety by reference to, our articles of incorporation and bylaws, each as amended. For more information, refer to our articles of incorporation and bylaws and any applicable provisions of relevant law, including the Virginia Stock Corporation Act (the “VSCA”) and federal laws governing banks and bank holding companies. Copies of the articles of incorporation and bylaws, each as amended, have been filed with the SEC.

Our authorized capital stock consists of (i) 150,000,000 shares of common stock, no par value per share, and (ii) 250,000 shares of preferred stock, par value $50.00 per share, of which 30,000 shares have been designated as the Company’s Mandatorily Convertible Cumulative Perpetual Preferred Stock, Series B, par value $50.00 per share and 10,000 shares have been designated as the Company’s Mandatorily Convertible Cumulative Perpetual Preferred Stock, Series C, par value $50.00 per share. As of June 30, 2024, there were (i) 73,503,647 shares of our common stock issued and outstanding held by approximately 3,500 holders of record, (ii) no shares of our Series B Preferred Stock issued and outstanding and (iii) 2,732 shares of our Series C Preferred Stock issued and outstanding held by approximately one (1) holder of record.

As of June 30, 2024, there were warrants outstanding to purchase 26,195,999 shares of our common stock and 1,441 shares of our Series C Preferred Stock. If the shares of the Series C Preferred Stock were mandatorily converted or exchanged into shares of our common stock pursuant to our articles of incorporation or the Exchange Agreement (as defined below), as is anticipated, the warrant to purchase 1,441 shares of our Series C Preferred Stock would automatically become a warrant to purchase (or, upon exercise, be exchangeable into) 5,764,000 shares of common stock.

As of June 30, 2024, there were options outstanding to purchase 29,741 shares of common stock and 828,139 shares of common stock subject to unvested restricted stock awards, all granted under our equity compensation plans.

Common Stock

General. Each share of our common stock has the same relative rights as, and is identical in all respects to, each other share of our common stock. The common stock is listed on the NYSE American market under the symbol “BRBS.” The transfer agent for our common stock is Computershare, Inc., 250 Royall Street, Canton, Massachusetts 02021.

Voting Rights. The holders of our common stock are entitled to one vote per share and, in general, a majority of votes cast with respect to a matter is sufficient to authorize action upon routine matters. Directors are elected by a plurality of the votes cast, and shareholders do not have the right to accumulate their votes in the election of directors.

Dividends. Our shareholders are entitled to receive dividends or distributions that the Company’s Board of Directors may declare out of funds legally available for those payments. The payment of distributions by the Company is subject to the restrictions of Virginia law applicable to the declaration of distributions by a corporation. A Virginia corporation generally may not authorize and make distributions if, after giving effect to the distribution, it would be unable to meet its debts as they become due in the usual course of business or if the corporation’s total assets would be less than the sum of its total liabilities plus the amount that would be needed, if it were dissolved at that time, to satisfy the preferential rights of shareholders whose rights are superior to the rights of those receiving the distribution. In addition, the payment of distributions to shareholders is subject to any prior rights of outstanding preferred stock.

11

As a bank holding company, our ability to pay dividends is affected by the ability of the Bank, our bank subsidiary, to pay dividends to the holding company. The ability of the Bank, as well as the Company, to pay dividends in the future is, and could be further, influenced by bank regulatory requirements and capital guidelines.

Liquidation Rights. In the event of any liquidation, dissolution or winding up of the Company, the holders of shares of our common stock will be entitled to receive, after payment of all debts and liabilities of the Company and after satisfaction of all liquidation preferences applicable to any preferred stock, all remaining assets of the Company available for distribution in cash or in kind.

Directors and Classes of Directors. Our Board of Directors is divided into three classes with directors serving staggered three-year terms. Currently, the Board of Directors consists of 18 directors. Under the VSCA, a director of the Company may be removed, with or without cause, by shareholders if the number of votes cast to remove such director constitutes a majority of the votes entitled to be cast at an election of directors of the voting group or voting groups by which such director was elected.

Preemptive Rights; Redemption and Assessment. Holders of shares of our common stock are not entitled to preemptive rights with respect to any shares that may be issued, other than as provided to (i) any Selling Shareholder (other than Mr. Spurzem) for so long as such Selling Shareholder owns at least 9.9% of the issued and outstanding common stock, pursuant to the Securities Purchase Agreement, and (ii) Mr. Spurzem for so long as he owns at least 4.9% of the issued and outstanding common stock, pursuant to the 2014/2015 Agreements. The common stock is not subject to redemption or any sinking fund, and the outstanding shares are fully paid and nonassessable.

Preferred Stock

General. The Board of Directors is empowered to authorize the issuance of shares of preferred stock, in one or more classes or series, at such times, for such purposes and for such consideration as it may deem advisable without shareholder approval. The Board of Directors may fix the designations, voting powers, preferences, participation, redemption, sinking fund, conversion, dividend and other relative rights, qualifications, limitations and restrictions of any such series of preferred stock.

Because the Board of Directors has the power to establish the preferences and rights of each series of preferred stock, it may afford the holders of any series of preferred stock voting, conversion or other rights that could adversely affect the voting power of the holders of common stock and, under certain circumstances, discourage an attempt by others to gain control of the Company.

The creation and issuance of any class or series of preferred stock, and the relative rights, designations and preferences of such class or series, if and when established, will depend upon, among other things, the future capital needs of the Company, then existing market conditions and other factors that, in the judgment of the Board of Directors, might warrant the issuance of preferred stock.

Our Board of Directors authorized the Series B Preferred Stock and Series C Preferred Stock in connection with the Private Placement. On June 28, 2024, all outstanding shares of the Series B Preferred Stock were automatically converted into shares of our common stock in the Conversion. We do not expect to issue additional shares of Series B Preferred Stock in the future and intend to remove the article in our articles of incorporation that established the Series B Preferred Stock in the future. We expect that the outstanding shares of Series C Preferred Stock will be exchanged for shares of our common stock during the third quarter of 2024 pursuant to the Exchange Agreement as described below.

12

Series C Preferred Stock.

Voting Rights. Holders of shares of Series C Preferred Stock do not have any voting rights with respect to such shares, except for certain protective matters such as amendments to our articles of incorporation that create any class or series of capital stock of the Company ranking senior to the Series C Preferred Stock.

Dividends. Following the Conversion, outstanding shares of Series C Preferred Stock are entitled to receive cumulative dividends, when, as and if declared by the Company’s Board of Directors, at the same date and in amounts equal to the number of shares of common stock into which each share of Series C Preferred Stock is then convertible, multiplied by the dividend declared and payable per share of common stock.

Liquidation Rights. In the event of any liquidation, dissolution or winding up of the Company, each holder of shares of Series C Preferred Stock will be entitled to receive, after payment of all debts and liabilities of the Company and after satisfaction of all liquidation preferences applicable to any preferred stock, pari passu with the common stock, all remaining assets of the Company available for distribution in cash or in kind.

Preemptive Rights; Redemption and Assessment. The shares of Series C Preferred Stock are not subject to redemption or any sinking fund. Holders of shares of Series C Preferred Stock do not have any rights to require redemption of their shares of Series C Preferred Stock nor any preemptive rights.

Terms of Conversion. Subject to certain ownership limitations, the shares of Series C Preferred Stock are convertible (or exchangeable) into shares of our common stock at the initial conversion rate of 4,000 shares of our common stock per each share of Series C Preferred Stock, which conversion rate is based on an initial conversion price of $2.50 per share of our common stock and is subject to certain adjustments.

Warrants

Pursuant to the Securities Purchase Agreement and the Spurzem Agreement, we issued warrants to purchase certain of the Company’s securities to the purchasers of our securities in the Private Placement and the Spurzem Placement, other than directors and executive officers of the Company. With the Conversion, as of June 30, 2024, the outstanding warrants (except for the warrant issued to Castle Creek) are exercisable into 26,195,999 shares of our common stock and, with respect to Castle Creek only, 1,441 shares of our Series C Preferred Stock (which stock is convertible or exchangeable into shares of our common stock in certain circumstances). The exercise price of the warrants for our common stock is $2.50 per share, other than with respect to Mr. Spurzem, who holds a warrant to purchase 2,428,000 shares of our common stock at an exercise price of $2.39 per share. The exercise price of the warrant to purchase 1,441 shares of our Series C Preferred Stock held by Castle Creek is $10,000 per share.

In the hands of certain holders, upon the conversion of all outstanding shares of our Series C Preferred Stock, the warrant to purchase shares of Series C Preferred Stock issued to Castle Creek will become exercisable for 5,764,000 shares of our common stock, and the exercise price will be $2.50 per share (assuming no adjustments are made pursuant to the terms of the warrant).

13

The warrants are exercisable at any time after issuance, and from time to time, in whole or in part until April 3, 2029 or, in the case of Mr. Spurzem, until June 13, 2029. Holders may exercise their warrants by paying the exercise price in immediately available funds to us or, in certain circumstances, through a “cashless exercise” whereby the holder of the warrant forfeits shares subject to the warrant in lieu of paying the exercise price.

The exercise price and number of shares of our common stock issuable upon exercise of the warrants may be adjusted in certain circumstances, including stock splits or dividends, mergers, consolidations, reclassifications, share exchanges, or upon the issuance of certain securities at a price per share that is deemed to be less than the exercise price per share under the warrants at the time of issuance.

Exchange Agreement

Simultaneous with entering into the Securities Purchase Agreement, the Company and Castle Creek entered into an Exchange Agreement, dated as of April 3, 2024 (the “Exchange Agreement”), whereby we agreed under certain conditions to issue shares of our common stock in exchange for shares of Series C Preferred Stock held by Castle Creek. Each exchange is subject to Castle Creek obtaining the necessary approvals and authorizations of, filings and registrations with, notifications to, or expiration or termination of any applicable waiting period under, the federal Change in Bank Control Act or any similar state laws. Subject to such approvals and other requirements contained in the Exchange Agreement, as of June 30, 2024, a total of 2,732 shares of Series C Preferred Stock and, if exercised, 1,441 shares of Series C Preferred Stock subject to a warrant held by Castle Creek, would be exchangeable pursuant to the Exchange Agreement into 10,928,000 shares and 5,764,000 shares of our common stock, respectively.

Liability and Indemnification of Directors and Officers

As permitted by the VSCA, our articles of incorporation contain provisions that indemnify our directors and officers to the full extent permitted by Virginia law and eliminate the personal liability of directors and officers for monetary damages to the Company or our shareholders in excess of one dollar, except to the extent such indemnification or elimination of liability is prohibited by the VSCA. These provisions do not limit or eliminate the rights of the Company or any shareholder to seek an injunction or any other non-monetary relief in the event of a breach of a director’s or officer’s fiduciary duty. In addition, these provisions apply only to claims against a director or officer arising out of his or her role as a director or officer and do not relieve a director or officer from liability if he or she engaged in willful misconduct or a knowing violation of the criminal law or any federal or state securities law.

In addition, our articles of incorporation provide for the indemnification of both directors and officers for expenses incurred by them in connection with the defense or settlement of claims asserted against them in their capacities as directors and officers. We have limited our exposure to liability for indemnification of directors and officers by purchasing directors’ and officers’ liability insurance coverage.

Stock Not Insured by the FDIC

Neither our common stock nor the Series C Preferred Stock is a deposit or a savings account and is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.

14

Anti-takeover Provisions of our Articles of Incorporation, Bylaws and Virginia Law

General. Certain provisions of our articles of incorporation and bylaws and Virginia law contain provisions that may have the effect of discouraging, delaying, or preventing a change in control of the Company by means of a tender offer, a proxy fight, open market purchases of shares of common stock, or otherwise in a transaction not approved by the Board of Directors. These provisions are designed to reduce, or have the effect of reducing, our vulnerability to coercive takeover practices and inadequate takeover bids. However, the existence of these provisions could prevent our shareholders from receiving a premium over the then prevailing market price of our common stock or a transaction that may otherwise be in the best interest of our shareholders. In addition, these provisions make it more difficult for our shareholders, should they choose to do so, to remove the Board of Directors or our management. The following is a summary of certain of these provisions.

The Company’s Articles of Incorporation and Bylaws.

Preferred Stock. Our articles of incorporation authorize the Board of Directors to establish one or more series of preferred stock and to determine, with respect to any series of preferred stock, the preferences, rights, and other terms of such series. Under this authority, the Board of Directors could create and issue a series of preferred stock with rights, preferences, or restrictions that have the effect of discriminating against an existing or prospective holder of our common stock as a result of such holder beneficially owning or commencing a tender offer for a substantial amount of common stock. One of the effects of authorized but unissued and unreserved shares of preferred stock may be to render it more difficult for, or to discourage an attempt by, a potential acquirer to obtain control of the Company by means of a merger, tender offer, proxy contest, or otherwise, and thereby protect the continuity of our management.

Classified Board of Directors. Our articles of incorporation and bylaws divide the Board of Directors into three classes, apportioned as evenly as possible, with directors serving staggered three-year terms. As a result, at least two annual meetings of shareholders may be required for the shareholders to replace a majority of the Board of Directors, subject to the shareholders’ ability to remove directors with or without cause by vote of the holders of a majority of our outstanding common shares. The classification of the Board of Directors makes it more difficult and time consuming to gain control of the Board of Directors.

Board Vacancies. Virginia law and our articles of incorporation and bylaws provide that any vacancy occurring on the Board of Directors may be filled by the remaining members of the board. These provisions may discourage, delay, or prevent a third party from voting to remove incumbent directors and simultaneously gaining control of the Board of Directors by filling the vacancies created by that removal with its own nominees.

Supermajority Voting Provisions. Our articles of incorporation provide that certain mergers or consolidations, share exchanges, acquisitions of control, sales of all or substantially all of our assets, liquidation or dissolution, in each case with a corporation, person or entity that is the beneficial owner, directly or indirectly, of more than 5% of the shares of our capital stock outstanding and entitled to vote on the transaction (a “significant shareholder”), must be approved by the affirmative vote of the holders of 80% of our outstanding capital stock entitled to vote on the transaction. If such an action does not involve a significant shareholder, it must be approved by the affirmative vote of the holders of more than two-thirds of our outstanding capital stock entitled to vote on the transaction. The voting provisions described in this paragraph do not apply to any transaction that is approved in advance by a majority of our directors (i) who were directors before the corporation, person or entity became a significant shareholder and who are not affiliates of such significant shareholder, and (ii) who became directors at the recommendation of the directors referred to in clause (i) above.

15

No Cumulative Voting. Our articles of incorporation do not provide for cumulative voting for any purpose. The absence of cumulative voting may afford anti-takeover protection by making it more difficult for our shareholders to elect nominees opposed by the Board of Directors.

Shareholder Meetings. Pursuant to our bylaws, special meetings of shareholders may only be called by our president or by request in writing stating the purposes thereof delivered to the president and signed by a majority of the directors or by three or more shareholders owning in the aggregate, not less than 20% in interest of the shares of our capital stock. This provision affords anti-takeover protection by making it more difficult for shareholders to call a special meeting of shareholders to consider a proposed merger or other business combination.

Advance Notification of Shareholder Nominations. Our bylaws establish advance notice procedures with respect to the nomination of persons for election as directors, other than nominations made by or at the direction of the Board of Directors. Pursuant to our bylaws, a shareholder entitled to vote for the election of directors may nominate persons for election to the Board of Directors by delivering written notice to our corporate secretary. With respect to an election to be held at an annual meeting of shareholders, our bylaws generally require that such notice be delivered not fewer than 60 days nor more than 90 days prior to the first anniversary of the preceding year’s annual meeting; provided, however, that if the date of the annual meeting is advanced by more than 30 days or delayed by more than 60 days from such anniversary date, notice by the shareholder must be delivered not earlier than the 90th day prior to such annual meeting and not later than the close of business on the later of the 60th day prior to such annual meeting or the 10th day following the day on which public announcement of the date of such meeting is first made. A shareholder wishing to nominate any person for election as a director must provide us with certain information concerning the nominee and the proposing shareholder.

Merger Considerations. Our articles of incorporation provide that the Board of Directors, when evaluating a transaction that would or may involve a change in control of the Company, shall consider, among other things, the following factors: the social and economic effects of the proposed transaction on the depositors, employees, suppliers, customers and other constituents of the Company and on the communities in which we operate or are located, the business reputation of the other party proposing the transaction and the evaluation of the then value of the Company in a freely negotiated sale and of the future prospects of the Company as an independent entity. This provision provides the Board of Directors the latitude to consider additional factors, aside from the price of a proposed merger or other business combination, in determining whether the transaction is in the best interests of the Company and our shareholders.

Virginia Anti-takeover Statutes. Virginia has two anti-takeover statutes: the Affiliated Transactions Statute and the Control Share Acquisitions Statute.

Affiliated Transactions Statute. Virginia law contains provisions governing affiliated transactions. An affiliated transaction generally is defined as any of the following transactions:

16

In general, these provisions prohibit a Virginia corporation from engaging in affiliated transactions with an interested shareholder for a period of three years following the date that such person became an interested shareholder unless:

After three years, any such transaction must be at a “fair price,” as statutorily defined, or must be approved by the holders of two-thirds of the voting shares, other than the shares beneficially owned by the interested shareholder.

The shareholders of a Virginia corporation may adopt an amendment to the corporation’s articles of incorporation or bylaws opting out of the Affiliated Transactions Statute. Neither our articles of incorporation nor our bylaws contain a provision opting out of the Affiliated Transactions Statute.

Control Share Acquisitions Statute. Virginia law also contains provisions relating to control share acquisitions, which are transactions causing the voting strength of any person acquiring beneficial ownership of shares of a Virginia public corporation to meet or exceed certain threshold percentages (20%, 33 1/3% or 50%) of the total votes entitled to be cast for the election of directors. Shares acquired in a control share acquisition have no voting rights unless:

The acquiring person may require that a special meeting of the shareholders be held to consider the grant of voting rights to the shares acquired in the control share acquisition.

Under Virginia law, a corporation’s articles of incorporation or bylaws may contain a provision opting out of the Control Share Acquisitions Statute. Neither our articles of incorporation nor our bylaws contain a provision opting out of the Control Share Acquisitions Statute.

17

SELLING SHAREHOLDERS

Securities Covered by this Prospectus Held by the Selling Shareholders

The table below sets forth information concerning the resale of the Securities by the Selling Shareholders. When we refer to the “Selling Shareholders” in this prospectus, including in the “Plan of Distribution” section of this prospectus, we mean the persons listed in the table below, and the pledgees, donees, transferees, or other successors in interest who later come to hold any of the Selling Shareholders’ interests in the Securities and to whom we owe an obligation to register such securities.

The Selling Shareholders acquired their Securities that are issued and outstanding shares of our common stock as of the date of this prospectus pursuant to the Private Placement that closed on April 3, 2024, the Spurzem Placement that closed on June 13, 2024, and the conversion of the shares of Series B Preferred Stock issued in the Private Placement and the Spurzem Placement into shares of common stock on June 28, 2024. The Selling Shareholders may acquire additional Securities after the date of this prospectus upon the exercise of warrants and the conversion or exchange of our Series C Preferred Stock, in each case, issued by us to certain Selling Shareholders in the Private Placement that closed on April 3, 2024 and the Spurzem Placement that closed on June 13, 2024.

We will not receive any proceeds from the resale of the Securities by the Selling Shareholders. We will, however, receive cash proceeds equal to the total exercise price of any warrants that are exercised for cash but will receive no cash if and to the extent that warrants are exercised pursuant to the net, or “cashless,” exercise feature of the warrants. Under the terms of the warrants, the number of shares issuable pursuant to such warrant may be limited, with certain exceptions, to the extent such issuance would (i) cause or result in such Selling Shareholder, together with its affiliates, being deemed to own, control or have the power to vote or dispose of securities which would represent more than 9.99% of the voting securities of any class or series of the Company’s capital stock outstanding at such time, (ii) otherwise cause such Selling Shareholder or any of its affiliates to be required to file a notice or application for approval under the Bank Holding Company Act of 1956, the Change in Bank Control Act of 1978 or any similar state or federal statute or (iii) require such Selling Shareholder or any of its affiliates to obtain the prior approval of any bank regulator.

The following table sets forth a list of the Selling Shareholders and their ownership of the Securities to be offered pursuant to this prospectus, and it is based on information provided to us by the Selling Shareholders. Since the date on which the Selling Shareholders provided us with such information, the Selling Shareholders may have sold, transferred or otherwise disposed of all or a portion of the Securities in a transaction exempt from the registration requirements of the Securities Act. Each of the Selling Shareholders may from time to time offer and sell any or all of the Securities set forth below relating to such Selling Shareholder pursuant to this prospectus. We do not know when or in what amounts each of the Selling Shareholders may offer the Securities for sale. It is possible that the Selling Shareholders will not sell any of the shares offered under this prospectus. Because the Selling Shareholders may sell all, some or none of the Securities, no estimate can be given as to the number of shares that will be held by the Selling Shareholders upon termination of this offering. For purposes of the table below, we have assumed that the Selling Shareholders will sell all the Securities being registered and will not acquire or dispose of beneficial ownership of any additional shares of our common stock.

Unless otherwise indicated in the footnotes to the following table, based on the information supplied to us by the Selling Shareholders, no Selling Shareholder is a broker-dealer or an affiliate of a broker-dealer. To the extent any Selling Shareholder is, or is affiliated with, a broker-dealer, it could be deemed to be an “underwriter” within the meaning of the Securities Act.

18

19

Material Relationships with the Registrant

Other than the acquisition of securities from us and as discussed below, the Selling Shareholders have not held any position or office or had any other material relationship with us or any of our predecessors or affiliates within the past three years.

20

Private Placement.

Board Representation. Pursuant to the Securities Purchase Agreement, Castle Creek is entitled to designate two individuals to be appointed to the Company’s and Blue Ridge Bank’s Boards of Directors, subject to any required bank regulatory approvals, waivers or non-objections. This right will continue for as long as Castle Creek, together with its respective affiliates, owns, in the aggregate, 9.9% or more of the outstanding shares of our common stock (counting as shares of common stock owned by Castle Creek, all shares of common stock into which the shares of Series C Preferred Stock owned by Castle Creek, together with its affiliates, are convertible or exchangeable and disregarding any limitations on ownership or prohibitions on conversion pursuant to the terms of the Series C Preferred Stock that may otherwise apply). In the event that Castle Creek’s ownership falls below 9.9%, but is at least 4.9%, of the outstanding shares of our common stock (as calculated in the preceding sentence), Castle Creek’s board designation rights will continue with respect to one board representative member. In the event Castle Creek’s ownership falls below either of the foregoing thresholds, its rights to designate such board representatives automatically will be assigned to Mr. Lehman, provided that he then holds the required ownership levels.

In addition, Mr. Lehman may, but is not required to, designate an additional individual to be appointed to the Company’s and Blue Ridge Bank’s Boards of Directors for as long as he owns at least 4.9% of the outstanding shares of our common stock. Such designation right is subject to any required bank regulatory approvals, waivers or non-objections.

As of the date of this prospectus, Castle Creek has designated Ciaran McMullan and Tony Scavuzzo as its board representatives and Mr. Lehman has designated Trevor Montano as his board representative, and such individuals are currently serving on the Boards of Directors of the Company and Blue Ridge Bank. In connection with the Company’s next annual meeting of shareholders, we will take appropriate actions to reduce the size of the Company’s and Blue Ridge Bank’s Boards of Directors to 13 and 14 members, respectively, including Castle Creek’s two representatives and Mr. Lehman’s representative.

Asset Resolution Plan. The Company and Mr. Lehman, with non-binding input from Castle Creek, will work together to identify specific work-out assets and develop and adopt a mutually agreeable asset resolution plan pursuant to which the Company will accelerate its work-out strategy with respect to those identified assets.

Gross-Up Rights. Selling Shareholders who purchased in the Private Placement and who own at least 9.9% of our issued and outstanding common stock (which, in the case of Castle Creek, includes all shares of common stock into which the shares of Series C Preferred Stock owned by Castle Creek are convertible or exchangeable and disregarding any limitations on ownership or prohibitions on conversion pursuant to the terms of the Series C Preferred Stock that may otherwise apply) have gross-up rights to acquire from the Company any equity or equity-linked securities (with certain exceptions) offered by the Company in order to enable such Selling Shareholder to maintain its proportionate ownership interest in the Company as immediately prior to such issuance. The purchase price payable by such Selling Shareholder upon exercise of its gross-up rights to maintain its proportionate common stock interest in the Company pursuant to the Securities Purchase Agreement is net of any underwriting discounts or sales commissions.

Indemnification. Subject to certain limitations, the Company will indemnify each Selling Shareholder who purchased in the Private Placement and certain of their related parties against losses in connection with breaches of the Securities Purchase Agreement and the other documents contemplated therein by the Company or in connection with the transactions contemplated by the Securities Purchase Agreement. Subject to certain limitations, each Selling Shareholder who purchased in the Private Placement will indemnify the Company and its affiliates and certain related persons against losses in connection with breaches of the Securities Purchase Agreement and the other documents contemplated therein by such Selling Shareholder.

21

Registration Rights Agreement. On April 3, 2024, the Company and the Selling Shareholders who purchased in the Private Placement entered into a Registration Rights Agreement (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, the Company will register for resale the Securities, which it is doing through the registration statement of which this prospectus forms a part. The Company will use its commercially reasonable efforts to cause the registration statement registering the Securities to be declared effective by the SEC and to keep such registration statement effective until the earlier of (i) such time as all of the securities covered by such registration statement have been publicly sold by such Selling Shareholders and (ii) the earliest to occur of the following: (A) a sale of the Securities pursuant to a registration statement or Rule 144 under the Securities Act (in which case, only with respect to such security sold by the Selling Shareholder); (B) the Securities becoming eligible for resale by the Selling Shareholder under Rule 144 under the Securities Act without the requirement for the Company to be in compliance with the current public information required thereunder and without volume or manner-of-sale restrictions; or (C) such securities cease to be outstanding.

If the Company fails to file the registration statement or have it declared effective by certain deadlines, if the registration statement ceases to remain effective, subject to specified grace periods, or if the Company fails to satisfy the current public information requirement of Rule 144(c)(1) under the Securities Act, then the Company will pay monthly liquidated damages to the Selling Shareholders who purchased in the Private Placement in an amount of one percent (1.0%) of the aggregate purchase price paid by such Selling Shareholder pursuant to the Securities Purchase Agreement for any unregistered Securities then held by such Selling Shareholder, subject to certain caps and limitations. The Company will pay all fees and expenses incident to the Company’s performance of its obligations under the Registration Rights Agreement, excluding (with certain exceptions) any underwriting discounts, selling commissions, fees of underwriters, selling brokers, dealer managers or similar securities industry professionals and all legal fees and expenses of legal counsel for any such Selling Shareholder. The Company and such Selling Shareholders agreed to provide each other with certain indemnification and contribution rights.

Exchange Agreement. Simultaneous with entering into the Securities Purchase Agreement, the Company and Castle Creek entered into the Exchange Agreement, whereby the Company agreed under certain conditions to issue shares of our common stock in exchange for shares of Series C Preferred Stock held by Castle Creek. Each exchange is subject to Castle Creek obtaining the necessary approvals and authorizations of, filings and registrations with, notifications to, or expiration or termination of any applicable waiting period under, the federal Change in Bank Control Act or any similar state laws.

Spurzem Placement.

Indemnification. Pursuant to the Spurzem Agreement, subject to certain limitations, the Company will indemnify Mr. Spurzem and certain of his related parties against losses in connection with breaches of the Spurzem Agreement and the other documents contemplated therein by the Company or in connection with the transactions contemplated by the Spurzem Agreement. Subject to certain limitations, Mr. Spurzem will indemnify the Company and its affiliates and certain related persons against losses in connection with breaches of the Spurzem Agreement and the other documents contemplated therein by Mr. Spurzem.

Registration Rights Agreement. On June 13, 2024, the Company and Mr. Spurzem entered in a registration rights agreement with terms substantially similar to the Registration Rights Agreement discussed under the heading “—Private Placement—Registration Rights Agreement.”

22

Spurzem Gross-Up Rights. For so long as he owns at least 4.9% of the issued and outstanding common stock pursuant to the 2014/2015 Agreements, Mr. Spurzem has gross-up rights with respect to certain issuances of equity or equity-linked securities by the Company. The purchase price payable by Mr. Spurzem upon exercise of his gross-up rights to maintain his proportionate common stock interest in the Company pursuant to the 2014/2015 Agreements is net of any underwriting discounts or sales commissions.

Directors and Officers of the Company.

Directors. William W. Stokes, G. William Beale, Carolyn J. Woodruff, Elizabeth H. Crowther, Heather M. Cozart, Hunter H. Bost, Julien G. Patterson, Mensel D. Dean, Jr., Otis S. Jones, Randolph N. Reynolds, Jr., Robert S. Janney, Vance H. Spilman and Trevor Montano serve on our Board of Directors. Additionally:

Officers. G. William Beale serves as our President and Chief Executive Officer. Judy C. Gavant serves as our Executive Vice President and Chief Financial Officer.

Directors and Officers of Blue Ridge Bank.

Directors. William W. Stokes, G. William Beale, Carolyn J. Woodruff, Elizabeth H. Crowther, Heather M. Cozart, Hunter H. Bost, Julien G. Patterson, Mensel D. Dean, Jr., Otis S. Jones, Randolph N. Reynolds, Jr., Robert S. Janney, Vance H. Spilman, Trevor Montano and Judy C. Gavant serve on the Board of Directors of Blue Ridge Bank.

Officers. G. William Beale serves as the Chief Executive Officer of Blue Ridge Bank. Judy C. Gavant serves as President and Chief Financial Officer of Blue Ridge Bank.

23

PLAN OF DISTRIBUTION

We are registering the shares of our common stock issued or to be issued to the Selling Shareholders and issuable upon exercise of the warrants issued to the Selling Shareholders to permit the resale of these shares of common stock by the holders of the shares of our common stock and warrants from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the Selling Shareholders of the shares of our common stock. We will bear all fees and expenses incident to our obligation to register the shares of our common stock.

The Selling Shareholders may sell all or a portion of the shares of our common stock beneficially owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the shares of our common stock are sold through underwriters or broker-dealers, the Selling Shareholders will be responsible for underwriting discounts or commissions or agent’s commissions. The shares of our common stock may be sold on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the over-the-counter market or in transactions otherwise than on these exchanges or systems or in the over-the-counter market and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. The Selling Shareholders may use any one or more of the following methods when selling shares:

The Selling Shareholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, as permitted by that rule, or Section 4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of those provisions.

Broker-dealers engaged by the Selling Shareholders may arrange for other broker-dealers to participate in sales. If the Selling Shareholders effect such transactions by selling shares of our common stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Shareholders or commissions from purchasers of the shares of our common stock for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with Financial Institution Regulatory Authority (“FINRA”) Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.

In connection with sales of the shares of our common stock or otherwise, the Selling Shareholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the shares of our common stock in the course of hedging in positions they assume. The Selling Shareholders may also sell shares of our common stock short and if such short sale shall take place after the date that the registration statement of which this prospectus is a part is declared effective by the SEC, the Selling Shareholders may deliver shares of our common stock covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales. The Selling Shareholders may also loan or pledge shares of our common stock to broker-dealers that in turn may sell such shares, to the extent permitted by applicable law. The Selling Shareholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). Notwithstanding the foregoing, the Selling Shareholders have been advised that they may not use shares registered on this registration statement to cover short sales of our common stock made prior to the date the registration statement of which this prospectus forms a part has been declared effective by the SEC.

The Selling Shareholders may, from time to time, pledge or grant a security interest in some or all of the warrants or shares of our common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of our common stock from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending, if necessary, the list of Selling Shareholders to include the pledgee, transferee or other successors in interest as Selling Shareholders under this prospectus. The Selling Shareholders also may transfer and donate the shares of our common stock in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

The Selling Shareholders and any broker-dealer or agents participating in the distribution of the shares of our common stock may be deemed to be “underwriters” within the meaning of Section 2(a)(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such broker-dealer or agent and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Selling stockholders who are “underwriters” within the meaning of Section 2(a)(11) of the Securities Act will be subject to the applicable prospectus delivery requirements of the Securities Act including Rule 172 thereunder and may be subject to certain statutory liabilities of, including but not limited to, Sections 11, 12 and 17 of the Securities Act and Rule 10b-5 under the Exchange Act.

Each Selling Shareholder has informed us that it is not a registered broker-dealer and does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute shares of our common stock. Upon our being notified in writing by a Selling Shareholder that any material arrangement has been entered into with a broker-dealer for the sale of our common stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule 424(b) under the Securities Act, disclosing (i) the name of each such Selling Shareholder and of the participating broker-dealer(s), (ii) the number of shares involved, (iii) the price at which such shares of our common stock were sold, (iv) the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus, and (vi) other facts material to the transaction. In no event shall any broker-dealer receive fees, commissions and markups, which, in the aggregate, would exceed eight percent (8.0%).

24

Under the securities laws of some states, the shares of our common stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares of our common stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with.

There can be no assurance that any Selling Shareholder will sell any or all of the shares of our common stock registered pursuant to the registration statement of which this prospectus forms a part.

Each Selling Shareholder and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of shares of our common stock by the Selling Shareholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the shares of our common stock to engage in market-making activities with respect to the shares of our common stock. All of the foregoing may affect the marketability of the shares of our common stock and the ability of any person or entity to engage in market-making activities with respect to the shares of our common stock.

We will pay all expenses of the registration of the shares of our common stock including, without limitation, SEC filing fees and expenses of compliance with state securities or “blue sky” laws; provided, however, that each Selling Shareholder will pay all underwriting discounts and selling commissions, if any and any related legal expenses incurred by it. We will indemnify the Selling Shareholders against certain liabilities, including some liabilities under the Securities Act, in accordance with the registration rights agreement enter into by the Company with the Selling Shareholders in connection with the Private Placement and the Spurzem Placement, or the Selling Shareholders will be entitled to contribution. We may be indemnified by the Selling Shareholders against civil liabilities, including liabilities under the Securities Act, that may arise from any written information furnished to us by the Selling Shareholders specifically for use in this prospectus, in accordance with the related registration rights agreement, or we may be entitled to contribution.

25

LEGAL MATTERS

Unless otherwise specified in the applicable prospectus supplement, Williams Mullen, Richmond, Virginia, our legal counsel, will pass upon the validity of the securities being offered through this prospectus.

EXPERTS

The consolidated financial statements of Blue Ridge Bankshares, Inc. and its subsidiaries as of December 31, 2023 and 2022, and for the three years ended on December 31, 2023, 2022 and 2021, incorporated into this prospectus and the registration statement by reference from our Annual Report on Form 10-K for the year ended December 31, 2023, as amended, have been audited by Elliott Davis, PLLC, an independent registered public accounting firm, as stated in their report appearing in such Form 10-K. Such report of Elliott Davis, PLLC is incorporated herein and in the registration statement by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

26

BLUE RIDGE BANKSHARES, INC.

PROSPECTUS

July 29, 2024